drugset / Trial / NCT00162526

Tocopherol is a Novel Treatment for Cancer Related Mucositis

NCT00162526

Phase 2 Withdrawn 30 enrolled Hadassah Medical Organization
RandomizedSingle-groupDouble-blindTreatment

Summary

The present protocol is an attempt to prevent/treat mucositis in highly susceptible patients subjected to maximally tolerated doses of subsequently-myeloablative or myeloablative doses of chemoradiotherapy supported by autologous or allogeneic stem cell transplantation at the Department of Bone Marrow Transplantation. Mucositis is a major problem in the management of transplant recipients which subjects the patients to the risk of sepsis, need for parenteral nutrition and need of narcotics. We are planning a 2 arm study, comparing 2 safe vitamin E based formulations with placebo.

Timeline

Start
2005-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin E Other / unclassified